Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints

French drugmaker Sanofi SA's new Toujeo diabetes drug won U.S. regulatory approval, but with wording on its prescribing label that analysts say could make marketing difficult. Toujeo is a more potent follow-up to the drugmaker's top-selling Lantus insulin product, which accounts for a fifth of Sanofi sales. Sanofi is hoping to convert patients to Toujeo as Lantus is due to lose its U.S. patent protection this month. The U.S. Food and Drug Administration late Wednesday approved the once daily, long-acting basal insulin to treat type 1 and the far more prevalent type 2 diabetes.



via Health News Headlines - Yahoo News http://ift.tt/1FwEiXf